Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $14.9 million.

  • China Pharma Holdings' Liabilities and Shareholders Equity rose 17.37% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.7 million, marking a year-over-year decrease of 2.83%. This contributed to the annual value of $14.9 million for FY2024, which is 9.60% down from last year.
  • Per China Pharma Holdings' latest filing, its Liabilities and Shareholders Equity stood at $14.9 million for FY2024, which was down 9.60% from $16.5 million recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Liabilities and Shareholders Equity peaked at $22.6 million during FY2021, and registered a low of $14.9 million during FY2024.
  • Over the past 3 years, China Pharma Holdings' median Liabilities and Shareholders Equity value was $16.5 million (recorded in 2023), while the average stood at $16.4 million.
  • In the last 5 years, China Pharma Holdings' Liabilities and Shareholders Equity increased by 7.25% in 2021 and then declined by 21.48% in 2022.
  • Yearly analysis of 5 years shows China Pharma Holdings' Liabilities and Shareholders Equity stood at $21.1 million in 2020, then increased by 7.25% to $22.6 million in 2021, then decreased by 21.48% to $17.8 million in 2022, then dropped by 7.39% to $16.5 million in 2023, then fell by 9.60% to $14.9 million in 2024.